EBD GmbH is part of the Knowledge & Networking Division of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
 
BioPharm America 2014 EBD Group MassBio

Share/Follow Us

Share this:
Follow this event:
Follow us on Twitter
Subscribe to our newsletters:

BioPharm America™ 2015 Program Overview

www.ebdgroup.com/bpa/program
Monday, September 14, 2015
6:00–8:00 pm
Level 3, Atrium Lobby
Welcome Reception

BioPharm America™ 2015 Welcome Reception
All BioPharm America attendees are cordially invited to join us for a welcome reception.

Boston Marriott Copley Place
Level 3, Atrium Lobby
110 Huntington Avenue
Boston, MA 02116 (map)

You will be able to pick up your name badge at the welcome reception.

Tuesday, September 15, 2015
7:30 am
Level 3, Atrium Lobby
7:30 am
Level 4, Grand Ballroom
Exhibition opens and Continental Breakfast
8:30–10:40 am
Level 3, Wellesley
Pharma and Large Biotech Presentations
9:00–10:30 am
Parallel Workshops
The perfect pitch: Do you have what it takes to win over investors?

Tuesday, 9:00–10:30 am
Level 3, Simmons

What you have to say in 30 seconds could mean the difference between a meeting with an investor and a door closed in your face. Win a one-to-one meeting with a leading life science private equity investor.

Members of the audience will have 30 seconds to give their elevator pitch to a star-studded panel of seasoned industry investors. The top picks will be selected for a second round that includes two minutes of presentation and/or Q&A time with the judges. First- and second-place winners will receive a full 30-minute private follow-up meeting with the panelist of their choice. Judges will receive a written summary of all participant pitches and their scores, should they wish to follow up on their own. All are welcome: entrepreneurs, service providers, job seekers, executives and more.

Audience preparation notes:
Participants will be judged on the quality and effectiveness of the overall 30-second pitch. Remember, the primary goal of an elevator pitch is to spark interest for a follow-up meeting. Pre-workshop coaching is available from the moderator (contact: doug@macbiocom.com). Practice, practice, practice!

Moderator:
Douglas MacDougall – President, MacDougall Biomedical Communications

Judges:
  • Richard Anders – Founder, Executive Director, Mass Medical Angels
  • Bernard Davitian – VP and Managing Director, Sanofi-Genzyme BioVentures
  • Peter Kolchinsky – Managing Director and Portfolio Manager, RA Capital
  • Sara M. Nayeem – Principal, New Enterprise Associates
  • Marta New – Principal, Baxalta Ventures
  • Dennis J. Purcell – Founder and Senior Advisor, Aisling Capital
  • Geoffrey von Maltzahn – VentureLabs Partner, Flagship Ventures
BioPharm America™ 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Big data: Going from buzzword to business

Tuesday, 9:00–10:30 am
Level 4, Provincetown

From genomics to drug discovery to compliance, the amount of data the biopharma industry has the ability collect and analyze is staggering. But, there are many questions to be addressed: How can we effectively mine the data to make impactful decisions in R&D? What information is being assessed by payers? Why are certain areas of biotech getting funded where others are not? This panel will address these questions and discuss how big data is being used to help companies more efficiently design clinical studies, enroll targeted patients, and ultimately help drive strategic business decisions.

BioPharm America™ 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
10:45 am–12:30 pm
Level 4, Salon G
Welcome and Opening Plenary Discussion
Welcome Remarks

Tuesday, 10:45–11:15 am
Level 4, Salon G

Speakers:
  • Anna Chrisman – Group Managing Director, EBD Group
  • Robert Coughlin – President and CEO, MassBio
BioPharm America™ 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Opening Plenary Discussion
Giving up the corporate jet and going back to the trenches: Insights from biotech disrupters

Tuesday, 11:15 am–12:30 pm
Level 4, Salon G

There is an increasing number of industry heavy hitters who have successfully led and exited large corporations and are now investing their experience, clout and in some cases, personal finances to reseed the life science ecosystem by leading the charge at small companies. Join us as they provide their perspectives from both sides of the fence, share the "war stories" that got them to where they are, and discuss how their experiences are helping them drive innovative small companies to successfully attack difficult targets at the front lines.

Moderator:
Francois Maisonrouge – Senior Managing Director, Evercore Partners

Panelists:
  • Deborah Dunsire – President and CEO, FORUM Pharmaceuticals
  • Jeffrey B. Kindler – CEO, Centrexion Corp.
  • Jeremy Levin – Chairman and CEO, Ovid Therapeutics Inc.
  • Christopher A. Viehbacher – Managing Partner, Gurnet Point Capital
BioPharm America™ 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Moderator:
Francois Maisonrouge Francois Maisonrouge
Senior Managing Director
Evercore Partners

Speakers:
Deborah Dunsire Jeffrey B. Kindler Jeremy Levin Christopher A. Viehbacher
Deborah Dunsire
President and CEO
FORUM Pharmaceuticals
Jeffrey B. Kindler
CEO
Centrexion Corp.
Jeremy Levin
Chairman and CEO
Ovid Therapeutics Inc.
Christopher A. Viehbacher
Managing Partner
Gurnet Point Capital
12:30–1:30 pm
Level 4, Exhibit Hall
Luncheon
1:30–2:30 pm
Executive Discussion
Rare diseases: The new norm?

Tuesday, 1:30–2:30 pm
Level 3, Simmons

With over 7,000 rare diseases and treatments for only 5% of them, the need for cures is obvious. With that need comes great opportunities—and risks—for drug developers. Though the therapeutic promises for the treatments of rare diseases are greater now than ever before, significant hurdles are in the way of getting patients access to innovative therapies. Heads of leading R&D companies and patient organizations will share their insights on the evolving landscape and discuss the importance of patient engagement and cross-sector collaborations in addressing the opportunities and challenges in financing, clinical trials, pricing, and patient access.

Moderator:
Jeremy Springhorn – Partner, Corporate Development, Flagship Ventures

Speakers:
  • Henri Termeer – Former CEO, President and Chairman, Genzyme Corporation
  • John Orloff – Executive VP, Global Head of R&D, Chief Scientific Officer, Baxalta
BioPharm America™ 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Level 4, Exhibit Hall
1:00–6:00 pm
One-to-one Meetings ►
2:45–6:15 pm
Parallel Panel Discussions
Dealmaking and Strategy
Externalizing R&D, building efficient pharma

Tuesday, 2:45–3:45 pm
Level 3, Simmons

While attempting to maintain a continuous number of potential products, big pharma has had to adjust their acquisition and investment strategy due to declining R&D productivity in recent years. This has resulted in a significant shift from internal to external R&D, allowing industry to focus on scouting the most promising developments in biotech. The panel will discuss what is unique to their individual searches and how they prioritize.

Moderator:
Bruce Booth – Partner, Atlas Venture

Panelists:
  • Irene Abrams – Senior Director, Technology and Innovation Development Office, Boston Children's Hospital
  • Daniel J. Curran – Head, Center for External Innovation, Takeda Pharmaceuticals
  • Rupert Vessey – Senior VP, Translational Development, Celgene
  • Robert Urban – Head, Johnson & Johnson Innovation, Boston
BioPharm America™ 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Immuno-oncology: New advances + new targets + new partnerships = new cures?

Tuesday, 4:00–5:00 pm
Level 3, Simmons

Big pharma has a strong foothold in immuno-oncology, but with new biotechs coming up with novel platforms and technologies, the field is more exciting now than ever before. How are these new advances making immunotherapies more effective and bringing us closer to cures? This panel will address this question, provide an overview of the current partnership landscape, then discuss what makes new partners attractive and what differentiates new targets.

BioPharm America™ 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Instant biotech: Creating a clinical-stage startup by in-licensing assets

Tuesday, 5:15–6:15 pm
Level 3, Simmons

With numerous acquisitions and mergers among big pharma, and more programs from academics and biopharma than investors are willing to fund, many innovative, clinical-stage products that don't fit the mold are being left on the shelf. This leaves entrepreneurs in a perfect position to create startup companies with an instant pipeline. The panelists will discuss the multitude of options available when creating a biotech company by in-licensing assets, as well as their strategy on securing funding and the difficulties along the way.

Moderator:
Jeffrey L. Quillen – Partner, Foley Hoag LLP

BioPharm America™ 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
In the Spotlight
2:45–3:45 pm
Digital health

Tuesday, 2:45–3:45 pm
Level 4, Provincetown

Digital health is steadily growing and providing advances in the way health data is collected, organized and analyzed, which will influence patient treatment plans of the future. In years to come doctors may not only prescribe medicine, but also recommend a digital program for treatment. This panel will discuss how digital health has the potential to change the way therapeutics companies incorporate digital health into overall patient treatment strategies.

Moderator:
Steve Dickman – CEO, CBT Advisors

Panelists:
  • Thomas Klein – Founder and CEO, Cytolon
  • Eddie Martucci – VP, PureTech
BioPharm America™ 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
How does pharma get involved in an outside-the-box idea?

Tuesday, 4:00–5:00 pm
Level 4, Provincetown

Every pharma company boasts about being innovation-driven, yet the majority of their R&D targets and approaches are in the same five therapeutic areas. Sit down with executives from pharma going after the white space areas to discuss why going into these overlooked areas alone can actually be wildly successful.

Moderator:
Chris Comeau – Partner, Ropes & Gray

Panelists:
  • Richard Andrews – President and CEO, Thrasos Therapeutics
  • Adam Keeney – VP and Global Head, External Innovation Operations, Sanofi
BioPharm America™ 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Biomarkers and precision medicine

Tuesday, 5:15–6:15 pm
Level 4, Provincetown

Advancements in biomarkers and precision medicine have the potential to radically change disease treatment and prevention. With greater understanding of individual patient information, more targeted and tailored treatment options are available. Panelists will discuss how the future of biomarkers and personalized medicine will impact R&D decisions and ultimately benefit patients.

BioPharm America™ 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
7:00–9:30 pm
Block Party Networking Reception
Technology Square

Technology Square
300/500 Technology Square Courtyard
Cambridge, MA

Step out into Cambridge's Technology Square for a Food Truck Block Party featuring some of Boston's most beloved food trucks. Sponsored by IMS Health, the Block Party reception joins biotech and culinary entrepreneurs together for an unforgettable evening of networking in Boston's biotech hub.

Sponsored by:
IMS HealthIMS Health

6:30–7:00 pm Shuttle buses will transport guests to the reception
8:45–9:30 pm Shuttle buses will transport guests to the conference hotel

Wednesday, September 16, 2015
7:30 am
Level 4, Foyer
7:30 am
Level 4, Grand Ballroom
Exhibition opens and Continental Breakfast
8:30–10:00 am
Level 3, Wellesley
Pharma and Large Biotech Presentations
Level 4, Exhibit Hall
8:00 am–6:00 pm
One-to-one Meetings ►
10:00 am–12:45 pm
Roundtable Discussions
Alternative partners roundtable

Wednesday, 10:00–10:45
Level 4, Provincetown

Clear methods are in place for how to approach pharma and even traditional investors but how do you get to the alternative partners that can make or break your startup? Venture philanthropists, patient groups, foundations and institutes discuss the best methods for getting the attention of all the other players.

Moderator:
Angus McQuilken – VP, Marketing and Communications, Massachusetts Life Sciences Center

Panelists:
  • Christopher de Souza – Director, Broadview Ventures
  • Gary M. Sclar – Associate Director, Dana-Farber Cancer Institute
BioPharm America™ 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Pharma roundtable

Wednesday, 11:00–11:45
Level 4, Provincetown

Hear directly from your potential deal partners (large and small): What are they are looking for? Where do they source from? How do you get their attention? Execs from the leading pharma companies will share "dos and don'ts" and other helpful advice going into your afternoon pitches.

Panelists:
  • Frank Borriello – VP, Head of Search and Evaluation, Global Business Development, Baxalta
  • Paola Casarosa – Corporate VP, Business Development and Licensing/Prescription Medicines, Boehringer Ingelheim GmbH
  • Tomas Landh – Innovation Sourcing VP, Senior Principal Scientist, Novo Nordisk
  • Melinda Richter – Head, Johnson & Johnson Innovation, JLABS
BioPharm America™ 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Investor roundtable

Wednesday, 12:00–12:45
Level 4, Provincetown

Investors from both corporate and financial venture firms will highlight innovative financing methods for early stage companies. We will cover topics that include:

  • VCs making seed-stage investments;
  • VC approaches to angel-backed companies; and
  • VCs doing mega-Series A rounds.

We'll emphasize the different approaches VCs take in investing in therapeutics, diagnostics, medical devices and the rapidly growing field of digital health. And we'll explore the flourishing collaboration between investors who have corporate backers (especially pharmaceutical companies) and those who are pure financial investors.

Moderator:
Steve Dickman – CEO, CBT Advisors

Panelists:
  • Marian Nakada – VP, Venture Investments, Johnson & Johnson Innovation, Boston
  • Isai Peimer – Managing Director, MedImmune Ventures
  • Geeta Vemuri – Managing Partner, Baxalta Ventures
BioPharm America™ 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
11:00 am–12:30 pm
Company Presentations ►
12:30–1:30 pm
Level 4, Exhibit Hall
Luncheon
1:30–4:00 pm
Afternoon pitches by startup companies

Wednesday, 1:30–4:30 pm
Level 4, Provincetown

Pitch your startup to a panel of judges comprising BD execs, venture capitalists, and industry experts!

Qualifying startup companies are invited to pitch their company using no more than four slides (or no slides if you dare!) in four minutes. Our top-notch panel of judges will determine the winner by the quality and effectiveness of the pitch.

Moderator:
Douglas MacDougall – President, MacDougall Biomedical Communications

Judges:
  • Jeffrey Arnold – Member, Mass Med Angels and Boston Harbor Angels
  • Thomas Luby – Senior Director, New Ventures, Johnson & Johnson Innovation, Boston
  • Ivana Magovcevic-Liebisch – Senior VP and Head of Global Business Development, Teva Pharmaceuticals
  • Jason Rhodes – Partner, Atlas Venture
  • S. Edward Torres – Co-Founder and Managing Director, Lilly Ventures
BioPharm America™ 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
1:30–5:30 pm
Company Presentations ►
5:45–7:00 pm
Level 4, Grand Ballroom
Exhibit Hall Reception
Thursday, September 17, 2015
7:30 am
Level 4, Foyer
7:30 am
Level 4, Grand Ballroom
Exhibition opens and Continental Breakfast
8:30 am–12:30 pm
Company Presentations ►
Level 4, Exhibit Hall
8:00 am–3:00 pm
One-to-one Meetings ►
9:15–10:15 am
Opening Panel Discussion
The evolution of the Regen Med ecosystem: What's required for its growth and sustainability?

Thursday, 9:15–10:15
Level 4, Provincetown

The Boston-Cambridge area is rich with innovative biotech and regenerative medicine companies and is flush with cash from investors, but what's next? It takes more than hot technologies to build a viable business and more importantly, make an impact in patients' lives. What does the regenerative medicine and cell and gene therapy sector need to become sustainable long-term? Panelists will discuss the need for an integrated approach to building the necessary infrastructure for success and help define the critical roles of startups, established biopharma, clinicians, hospitals, manufacturers, and other stakeholders that can make or break this maturing industry.

Moderator:
Dolores Baksh – Innovation Leader, Cell Therapy Technologies, GE Healthcare

Panelists:
  • Chris Gemmiti – Business Development Lead, Wyss Institute for Biologically Inspired Engineering, Harvard University
  • Doug Kerr – Senior Director, Corporate Strategy and Portfolio Manager, Biogen
  • Gary M. Sclar – Associate Director, Dana-Farber Cancer Institute
BioPharm America™ 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
10:30 am–12:45 pm
Panel Discussions
Gene and cell therapy

Thursday, 10:30–11:30
Level 4, Provincetown

With breaking headlines on how gene therapy can transform the way we treat diseases, the sector is booming. This panel will discuss the latest industry advances, new partnerships, regulatory issues, and other exciting developments.

Moderator:
Brock Reeve – Executive Director, Harvard Stem Cell Institute

Panelists:
  • Frank Borriello – VP, Head of Search and Evaluation, Global Business Development, Baxalta
  • Robert Millman – CEO, Semma Therapeutics; Managing Director, MPM Capital
  • Stephen Potter – Chief Business Officer, AGTC
BioPharm America™ 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
11:45–12:45
Genome editing

Thursday, 11:45–12:45
Level 4, Provincetown

We have seen exciting progress in the field of gene editing but how are these advances being applied to cell therapy and disease modification? How are techniques used in the lab like CRISPR, TALENS and ZFNs being translated to real benefits in patients, especially those with hereditary diseases? In addition to the scientific advances, what regulatory issues will need to be addressed before we can see treatments? What can we expect to see in the near and long-term?

BioPharm America™ 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
12:30–1:30 pm
Level 4, Exhibit Hall
Luncheon
3:00–4:00 pm
Level 4, Exhibit Hall
Closing Reception
Arrow Up


© 2009–2015 EBD Group, Inc.